The US FDA has accepted Galderma's resubmitted Biologics License Application for its liquid toxin candidate, restarting a regulatory clock that the company hopes will end in a new approval. The agency's acceptance, confirmed in a filing notice reported by The Dermatology Digest, means the application is complete enough for substantive review. That's a procedural win, not an approval. But it matters.

Acceptance is the gate every BLA must pass. When the FDA declines to file an application, sponsors lose months. When it accepts, the review timeline begins. For Galderma, this resubmission follows an earlier attempt that did not clear that bar. The company has now revised its package and tried again — and the agency has agreed to look.

What is actually under review?

Galderma's candidate is a liquid formulation of a botulinum toxin. The company already markets a lyophilized — freeze-dried — toxin, Restylane-portfolio sibling Dysport, which requires reconstitution by the clinician before injection. A ready-to-use liquid formulation would remove that reconstitution step from the workflow.

The practical pitch is simple. Pre-mixed product could reduce preparation time in busy aesthetic practices. It could also cut the risk of preparation errors. That's the manufacturer's framing, and it should be read as such — a claim about workflow, not yet a claim backed by disclosed trial data in this filing notice.

What the notice does not specify is the full indication being sought, the review classification, or a target action date. Those details typically follow formal acceptance. Derm Field will track the docket.

Why a resubmission, and why it matters

A refiling is a second chance. The original BLA for the liquid toxin was not accepted for filing, which meant the FDA considered the application incomplete on its face. Galderma has since addressed whatever gaps the agency identified — the company has not publicly detailed the specifics — and resubmitted.

For dermatology and aesthetics practices, the stakes are competitive. The injectable toxin market in the United States is dominated by a small number of products, and a liquid, ready-to-use entrant from a major manufacturer would be the first of its kind if approved. Galderma, fresh from its 2024 initial public offering on the SIX Swiss Exchange, has made neuromodulators a pillar of its portfolio strategy alongside its filler and skincare lines.

The takeaway in plain words: the FDA now has the file, and the review is officially underway.

What happens next

The standard BLA review path runs roughly ten to twelve months from acceptance, with priority review shortening that considerably. Galderma has not said which track applies here. An approval would give the company a differentiated toxin offering in a market where convenience claims increasingly drive switching behavior among injectors.

No trial results, dosing specifics, or formulation parameters were disclosed in the acceptance notice. Until Galderma publishes that detail — or the FDA posts its review documents — the strongest statement supported by the record is this: the application is in, it passed the completeness check, and a decision now rests with the regulator.